MCM2p在乳腺癌组织的表达及其与雌激素受体、孕激素受体、C-erbB-2的相关性分析  

Expression of MCM2p and its correlative analysis in breast cancer

作　　者：杨挚鹰[1] 梁剑平[2] 陈森林[2] 粟占三[2] 谭三勤[1] 

机构地区：[1]湖南师范大学医学院,湖南长沙410006 [2]湖南省肿瘤医院,湖南长沙410013

出　　处：《中国现代医学杂志》2007年第12期1457-1459,共3页China Journal of Modern Medicine

摘　　要：目的探讨MCM2p在乳腺癌组织中的表达及起其与ER、PR和C-erbB-2的相关性。方法采用SP免疫组织化学方法检测68例原发性乳腺癌组织中MCM2p、ER、PR和C-erbB-2的表达。结果ER、PR阳性表达率随乳腺癌临床分期的增高和淋巴结的转移而逐渐降低,呈负相关。MCM2p、C-erbB-2阳性表达率则随临床分期的增高和淋巴结的转移而逐渐增高,呈正相关,也与核分裂指数呈正相关。MCM2p的表达与ER和PR的表达状况关系密切,呈负相关。MCM2p与C-erbB-2的表达呈正相关。结论MCM2p可以作为乳腺癌预后判断的有价值的参考指标。[Objective] To determine expression and significance of MCM2p in breast cancer, and analyze the correlation of MCM2p, ER, PR and C-erbB-2. [Methods] The expression of MCM2p, ER, PR and C-erbB-2 was examined in breast cancer （n =68） with immunohistochemistry. [Results] ER and PR positive expression had a neg- ative relationship to pathologic stage and lymph node metastasis. MCM2p and C-erbB-2 positive expression showed a positive correlation with these two clinic features, as well as with mitotic index. MCM2p had also a negative correlation with ER and PR, while C-erbB-2 reverse. [Conclusion] MCM2p may serve as a valuable marker of clinic treatment for breast cancer, and it may also help to predict the clinical outcome.

关 键 词：MCM2p 乳腺癌 免疫组织化学 

分 类 号：R446[医药卫生—诊断学]